PFIZER INC Cost of Goods Sold (Deprecated 2018-01-31)
PFIZER INC (PFE) reported Cost of Goods Sold (Deprecated 2018-01-31) of $2.56 billion for the 3-month period ending 2018-04-01, per its 10-Q filed 2018-05-10.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2018-05-10
- PFIZER INC cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-04-01 was $2.56B, a 3.85% increase year-over-year.
- PFIZER INC cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $3.26B, a 1.31% increase year-over-year.
- PFIZER INC cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-10-01 was $2.85B, a 7.71% decline year-over-year.
- PFIZER INC cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-07-02 was $2.66B, a 16.10% decline year-over-year.
- PFIZER INC cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $11.24B, a 8.83% decline from fiscal 2016.
- PFIZER INC cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $12.33B, a 27.79% increase from fiscal 2015.
- PFIZER INC cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $9.65B, a 0.74% increase from fiscal 2014.
- PFIZER INC cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $9.58B, a 0.09% decline from fiscal 2013.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 3 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|---|
| 2018-04-01 | $2.56B 10-Q · filed 2018-05-10 | $5.82B derived: sum of 2 quarters · filed 2018-05-10 | $8.67B derived: sum of 3 quarters · filed 2018-05-10 | $11.33B derived: sum of 4 quarters · filed 2018-05-10 | |
| 2017-12-31 | $3.26B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $6.11B derived: sum of 2 quarters · filed 2018-02-22 | $8.77B derived: sum of 3 quarters · filed 2018-02-22 | $11.24B 10-K · filed 2018-02-22 | |
| 2017-10-01 | $2.85B 10-Q · filed 2017-11-09 | $5.51B derived: sum of 2 quarters · filed 2017-11-09 | $7.98B 10-Q · filed 2017-11-09 | $11.20B derived: sum of 4 quarters · filed 2018-05-10 | |
| 2017-07-02 | $2.66B 10-Q · filed 2017-08-10 | $5.13B 10-Q · filed 2017-08-10 | $8.35B derived: sum of 3 quarters · filed 2018-05-10 | $11.43B derived: sum of 4 quarters · filed 2018-05-10 | |
| 2017-04-02 | $2.47B 10-Q · filed 2018-05-10 | $2.47B 10-Q · filed 2017-05-11 | $5.69B derived: sum of 2 quarters · filed 2018-05-10 | $8.77B derived: sum of 3 quarters · filed 2018-05-10 | $11.95B derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $3.22B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $6.30B derived: sum of 2 quarters · filed 2018-02-22 | $9.48B derived: sum of 3 quarters · filed 2018-02-22 | $12.33B 10-K · filed 2018-02-22 | |
| 2016-10-02 | $3.08B 10-Q · filed 2017-11-09 | $6.26B derived: sum of 2 quarters · filed 2017-11-09 | $9.11B 10-Q · filed 2017-11-09 | $12.52B derived: sum of 4 quarters · filed 2018-02-22 | |
| 2016-07-03 | $3.17B 10-Q · filed 2017-08-10 | $6.03B 10-Q · filed 2017-08-10 | $9.44B derived: sum of 3 quarters · filed 2018-02-22 | $11.65B derived: sum of 4 quarters · filed 2018-02-22 | |
| 2016-04-03 | $2.85B 10-Q · filed 2017-05-11 | $6.26B derived: sum of 2 quarters · filed 2018-02-22 | $8.48B derived: sum of 3 quarters · filed 2018-02-22 | $10.66B derived: sum of 4 quarters · filed 2018-02-22 | |
| 2015-12-31 | $3.41B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $5.63B derived: sum of 2 quarters · filed 2018-02-22 | $7.81B derived: sum of 3 quarters · filed 2018-02-22 | $9.65B 10-K · filed 2018-02-22 | |
| 2015-09-27 | $2.22B 10-Q · filed 2016-11-10 | $4.40B derived: sum of 2 quarters · filed 2016-11-10 | $6.24B 10-Q · filed 2016-11-10 | $8.94B derived: sum of 4 quarters · filed 2017-02-23 | |
| 2015-06-28 | $2.18B 10-Q · filed 2016-08-11 | $4.02B 10-Q · filed 2016-08-11 | $6.72B derived: sum of 3 quarters · filed 2017-02-23 | $9.09B derived: sum of 4 quarters · filed 2017-02-23 | |
| 2015-03-29 | $1.84B 10-Q · filed 2016-05-12 | $4.54B derived: sum of 2 quarters · filed 2017-02-23 | $6.91B derived: sum of 3 quarters · filed 2017-02-23 | $9.37B derived: sum of 4 quarters · filed 2017-02-23 | |
| 2014-12-31 | $2.70B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $5.07B derived: sum of 2 quarters · filed 2017-02-23 | $7.53B derived: sum of 3 quarters · filed 2017-02-23 | $9.58B 10-K · filed 2017-02-23 | |
| 2014-09-28 | $2.37B 10-Q · filed 2015-11-05 | $4.83B derived: sum of 2 quarters · filed 2015-11-05 | $6.88B 10-Q · filed 2015-11-05 | $9.67B derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-06-29 | $2.46B 10-Q · filed 2015-08-06 | $4.51B 10-Q · filed 2015-08-06 | $7.30B derived: sum of 3 quarters · filed 2016-02-29 | $9.59B derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-03-30 | $2.04B 10-Q · filed 2015-05-07 | $4.84B derived: sum of 2 quarters · filed 2016-02-29 | $7.13B derived: sum of 3 quarters · filed 2016-02-29 | $9.37B derived: sum of 4 quarters · filed 2016-02-29 | |
| 2013-12-31 | $2.79B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $5.08B derived: sum of 2 quarters · filed 2016-02-29 | $7.32B derived: sum of 3 quarters · filed 2016-02-29 | $9.59B 10-K · filed 2016-02-29 | |
| 2013-09-29 | $2.29B 10-Q · filed 2014-11-06 | $4.53B derived: sum of 2 quarters · filed 2014-11-06 | $6.79B 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | $2.24B 10-Q · filed 2014-08-07 | $4.50B 10-Q · filed 2014-08-07 | |||
| 2012-12-31 | $9.82B 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |